Tafinlar and Pepcid drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tafinlar (dabrafenib mesylate) and Pepcid (famotidine). Common drug interactions include death among females and death among males.

The phase IV clinical study analyzes what interactions people have when they take Tafinlar and Pepcid. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Tafinlar?

Tafinlar has active ingredients of dabrafenib mesylate. eHealthMe is studying from 16,304 Tafinlar users. Check the latest studies of Tafinlar.

What is Pepcid?

Pepcid has active ingredients of famotidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 55,774 Pepcid users. Check the latest studies of Pepcid.

On Jul, 26, 2026

20 people who take Tafinlar and Pepcid together, and have interactions are studied.

What are the common drug interactions of Tafinlar and Pepcid, by gender? *:

female:

Death
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
Hospitalisation
Nausea (feeling of having an urge to vomit)
Oedema peripheral (superficial swelling)
Rash

male:

Death
Pyrexia (fever)
Influenza like illness
Malignant neoplasm progression (cancer tumour came back)
Bacterial infection
Chest discomfort
Dyspnoea (difficult or laboured respiration)
Epistaxis (bleed from the nose)
Hepatic enzyme increased
Hypokalaemia (low potassium)

What are the common drug interactions of Tafinlar and Pepcid, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Death

50-59:

Chills (felling of cold)
Death
Decreased appetite
Fatigue (feeling of tiredness)
Headache (pain in head)
Influenza like illness
Pyrexia (fever)
Chest discomfort
Dyspnoea (difficult or laboured respiration)
Epistaxis (bleed from the nose)

60+:

Death
Bacterial infection
Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
Hospitalisation
Pneumonia

What are the existing conditions these people have? *

Malignant Melanoma (skin cancer rises from melancytes): 5 people, 25.00%
Neoplasm Malignant (cancer tumour): 3 people, 15.00%
Malignant Melanoma Stage Iv (the cancer has spread to other places in the body, such as the lung, liver, brain, bone, soft tissue, or gastrointestinal (gi) tract. cancer may have spread to places in the skin far away from where it first started): 2 people, 10.00%
Thyroid Cancer: 1 person, 5.00%
Skin Cancer: 1 person, 5.00%
Nausea (feeling of having an urge to vomit): 1 person, 5.00%
Metastatic Neoplasm (spreadable cancer tumour): 1 person, 5.00%
Metastases To Central Nervous System (cancer spreads to central nervous system): 1 person, 5.00%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 5.00%
Lung Carcinoma Cell Type Unspecified Stage Iv (the lung cancer has spread to other organs of the body, such as the other lung, brain, or liver): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tafinlar and Pepcid?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously